NanoValent Pharmaceuticals’ Scientific Advisory Board plays an important role in directing our R&D activities and focus on the development of innovative, targeted anticancer agents. Our board brings together a group of eminent academics and leading international experts in oncology, hematology, and pharmaceutical R&D.
Our board’s medical and scientific insight and guidance combined with the unique specialist expertise of NanoValent Pharmaceuticals, are crucial to overcome the challenges associated with our ongoing R&D activities to address unmet medical needs.
Information is available on request